B7-H1-expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets

Journal of Clinical Investigation

Volumn 124, Issue 10, 2014, Pages 4657-4667

  Kuang, Dong Ming ^a   Xiao, Xiao ^a   Zhao, Qiyi ^a   Chen, Min Min ^a   Li, Xue Feng ^a   Liu, Rui Xian ^a   Wei, Yuan ^a   Ouyang, Fang Zhu ^a   Chen, Dong Ping ^a   Wu, Yan ^a   Lao, Xiang Ming ^a   Deng, Hong ^a   Zheng, Limin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ANGIOGENESIS; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD; CANCER GROWTH; CANCER TISSUE; CELL EXPANSION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CELL CARCINOMA; MEMORY T LYMPHOCYTE; MONOCYTE; PHENOTYPE; POLARIZATION; PROTEIN INTERACTION; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; TH22 CELL; ANIMAL; CANCER TRANSPLANTATION; CELL SEPARATION; CYTOLOGY; FLOW CYTOMETRY; HEK293 CELL LINE; HELPER CELL; HEPG2 CELL LINE; IMMUNOLOGY; INFLAMMATION; LIVER TUMOR; MALE; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD274; CARCINOMA, HEPATOCELLULAR; CELL SEPARATION; FLOW CYTOMETRY; HEK293 CELLS; HEP G2 CELLS; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKINS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MONOCYTES; NEOPLASM TRANSPLANTATION; PHENOTYPE; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84907495527     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74381     Document Type: Article

References (48)

1. Wolk K, Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 2006;17(5):367-380.
2. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol. 2011;12(5):383-390.
3. Rubino SJ, Geddes K, Girardin SE. Innate IL-17 and IL-22 responses to enteric bacterial pathogens. Trends Immunol. 2012;33(3):112-118.
4. Kamanaka M, et al. Memory/effector (CD45R-B(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med. 2011;208(5):1027-1040.
5. Qin WZ, et al. Expressions of IL-22 in circulating CD4+/CD8+ T cells and their correlation with disease activity in SLE patients. Clin Exp Med. 2011;11(4):245-250.
6. Feng D, et al. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology. 2012;143(1):188-198.
7. Mitra A, Raychaudhuri SK, Raychaudhuri SP. Functional role of IL-22 in psoriatic arthritis. Arthritis Res Ther. 2012;14(2):R65.
8. Ma HL, et al. IL-22 is required for Th17 cellmediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118(2):597-607.
9. Eyerich S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119(12):3573-3585.
10. Gurney AL. IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol. 2004;4(5):669-677.
11. Zheng Y, et al. Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007;445(7128):648-651.
12. Ma HL, et al. IL-22 is required for Th17 cellmediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118(2):597-607.
13. Liang SC, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203(10):2271-2279.
14. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10(8):857-863.
15. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T (H)-17, T (H) 1, and T (H) 2 cells. Nat Immunol. 2009;10(8):864871.
16. Reis E Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol. 2004;16(1):21-25.
17. Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009;125(7):1640-1648.
18. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology. 2010;51(1):154-164.
19. Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM, Zheng L. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood. 2007;110(2):587-595.
20. Kuang DM, Zhao Q, Xu J, Yun JP, Wu C, Zheng L. Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent pathways. J Immunol. 2008;181(5):3089-3098.
21. Liu T, et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol. 2012;32(6):1332-1339.
22. Kirchberger S, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med. 2013;210(5):917-931.
23. Kim K, Kim G, Kim JY, Yun HJ, Lim SC, Choi HS. Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation. Carcinogenesis. 2014;35(6):1352-1361.
24. Kryczek I, et al. IL-22 (+) CD4 (+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity. 2014;40(5):772-784.
25. 2+ T cells correlate with pancreatic cancer progression. Pancreas. 2014;43(3):470-477.
26. Jiang R, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology. 2011;54(3):900-909.
27. Kong X, et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis. Hepatology. 2012;56(3):1150-1159.
28. Wolk K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36(5):1309-1323.
29. Lee YK, et al. Late developmental plasticity in the T helper 17 lineage. Immunity. 2009;30(1):92-107.
30. 2+ T cells. J Immunol. 2009;182(4):2124-2130.
31. 2+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol. 2011;186(7):4388-4395.
32. Annunziato F, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204(8):1849-1861.
33. Messi M, Giacchetto I, Nagata K, Lanzavecchia A, Natoli G, Sallusto F. Memory and flexibility of cytokine gene expression as separable properties of human TH1 and TH2 lymphocytes. Nat Immunol. 2003;4(1):78-86.
34. 2+ central memory T cells. J Exp Med. 2004;200(6):725-735.
35. Zhou L, et al. TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORgammat function. Nature. 2008;453(7192):236-240.
36. McGeachy MJ, et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T (H)-17 cell-mediated pathology. Nat Immunol. 2007;8(12):1390-1397.
37. Volpe E, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T (H)-17 responses. Nat Immunol. 2008;9(6):650-657.
38. Zhao Q, et al. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol. 2011;41(8):2314-2322.
39. Kuang DM, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206(6):1327-1337.
40. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467-477.
41. Brahmer JR, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
42. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5):662-673.
43. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
44. Taube JM, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.
45. 2+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. J Immunol. 2012;188(3):1117-1124.
46. 2+ T cells in hepatocellular carcinoma patients. J Immunol. 2010;185(3):1544-1549.
47. Wu Y, Zhao Q, Peng C, Sun L, Li XF, Kuang DM. Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop. J Pathol. 2011;225(3):438-447.
48. Kuang DM, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 2011;54(5):948-955.